USP30 and Parkinson disease: Based on the seminal preclinical findings that demonstrated that MTX325 (previously known as MTX115325) protects dopaminergic neurons by promoting mitophagy, Mission Therapeutics initiated a landmark Phase 1 first‐in‐human clinical trial of MTX325, a selective USP30 inhibitor, early in 2024 (https://missiontherapeutics.com/mission‐therapeutics‐commences‐landmark‐trial‐of‐mtx325‐a‐potential‐disease‐modifying‐treatment‐for‐parkinsons‐disease/).